Ruoyang Liu

Recombinant Super-Compound Interferon (rSIFN-co) Versus Interferon Alfa in the Treatment of Moderate-to-Severe COVID-19: A Multicentre, Randomised, Phase 2 Trial

Zheng-Yang Shi, N. Xiong, F. Luo, 2020 .

Epidemiological characteristics and clinical features of 32 critical and 67 noncritical cases of COVID-19 in Chengdu

N. Zhang, Hong Chen, Yilan Zeng, 2020, Journal of Clinical Virology.

Effect of a genetically engineered interferon-alpha versus traditional interferon-alpha in the treatment of moderate-to-severe COVID-19: a randomised clinical trial

Zheng-Yang Shi, N. Xiong, Wei-min Li, 2021, Annals of medicine.

Engineered interferon alpha effectively improves clinical outcomes of COVID-19 patients

Dan Liu, Zheng-Yang Shi, N. Xiong, 2020 .